Cargando…
Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment
INTRODUCTION: Emerging evidence in estrogen receptor-positive breast cancer supports the notion that prolactin-Stat5 signaling promotes survival and maintenance of differentiated luminal cells, and loss of nuclear tyrosine phosphorylated Stat5 (Nuc-pYStat5) in clinical breast cancer is associated wi...
Autores principales: | Yang, Ning, Liu, Chengbao, Peck, Amy R, Girondo, Melanie A, Yanac, Alicia F, Tran, Thai H, Utama, Fransiscus E, Tanaka, Takemi, Freydin, Boris, Chervoneva, Inna, Hyslop, Terry, Kovatich, Albert J, Hooke, Jeffrey A, Shriver, Craig D, Rui, Hallgeir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978581/ https://www.ncbi.nlm.nih.gov/pubmed/24004716 http://dx.doi.org/10.1186/bcr3467 |
Ejemplares similares
-
Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression
por: Sato, Takahiro, et al.
Publicado: (2013) -
Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms
por: Peck, Amy R, et al.
Publicado: (2016) -
Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes
por: Peck, Amy R, et al.
Publicado: (2012) -
Selection of optimal quantile protein biomarkers based on cell-level immunohistochemistry data
por: Yi, Misung, et al.
Publicado: (2023) -
Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism
por: Goodman, C R, et al.
Publicado: (2016)